SRF



Growth signs after two years of pain

31 January 2025

SRF (SRF IN) has run up 25% in the past three months and outperformed the benchmark Nifty Index (down 4%), due to initial signs of demand recovery in Q3FY25 (as evidenced in Chemicals plays that have reported results so far). Per SRF, there is high possibility that Q4 would be better than Q3 and the worst is behind. However, do remain cautious as regards full demand and price recovery in FY26. So, we raise FY26E/27E EPS estimates by 8%/18% as also TP to INR 3,071 (from INR 2,232). We revise SRF to Accumulate from Reduce due to signs of recovery after two years of a drop in earnings, but risk-reward is not very favorable. The stock is trading at 35.4x FY27E P/E (45% PAT CAGR in FY25E-27E).

Chemicals segment drives earnings: SRF reported EBITDA of INR 6.2bn (Elara: INR 4.7bn), up 9%/15% YoY/QoQ, mainly due to growth in Chemicals (specialty chemicals and refrigerants) and Packaging Films. Consequently, PAT was up 7%/35% YoY/QoQ to INR 2.7bn (Elara: INR 1.7bn). In Q3, the Chemicals and Packaging Films segments witnessed a growth in revenue.

Chemicals – Refrigerants and Specialty Chemicals witnessed recovery: Chemicals segment (comprising 43% of revenue and 69% of EBIT) witnessed a revenue growth of 7%/10% YoY/QoQ to INR 15.0bn, though still 29% lower than the segment's peak revenue in Q4FY23. The segment's EBIT margin increased to 24.3% from 23.1% YoY and 18.1% QoQ. While the Specialty Chemicals business saw some impact of inventory build-up, overall improvement QoQ was seen, with partial recovery in the Agrochem segment. Refrigerants demand from OEMs in the domestic market boosted the segment's performance. SRF expects better Q4 performance for the segment with refrigerant gas pricing expected to sustain and recovery in agrochem intermediates.

Packaging Films and Technical Textiles – YoY volume recovery: SRF's Technical Textiles segment (comprising 15% of revenue and 11% of EBIT) saw a margin dip to 11.6% (versus 15.0% YoY) in Q3FY25. The segment was hit by weak demand and margins in belting fabrics. EBIT margin for the Packaging Films business (comprising 40% of revenue and 17% of EBIT) expanded by 241bps/70bps YoY/QoQ to 6.5% (Elara: 6.0%). BOPET and BOPP segments saw improved performance with some demand growth.

Revise to Accumulate from Reduce; TP raised to INR 3,071 from INR 2,232: We raise FY26E/27E EPS by 8%/18% due to better demand and pricing environment after Q3FY25 management commentary. However, we still await commentary from global major chemical players as regards CY25 demand outlook.

We raise TP to INR 3,071 from INR 2,232. We value SRF on DCF, assuming a 5.0% terminal growth rate and a 9.8% WACC (unchanged), average EBITDA margin of 19.8% (from 19.2%) in FY25E-27E and 22.6% in FY27E-30E (from 21.3%).

(ev	Financials

,					
YE March	FY23	FY24	FY25E	FY26E	FY27E
Revenue (INR mn)	148,703	131,385	142,211	162,205	191,414
YoY (%)	19.6	(11.6)	8.2	14.1	18.0
EBITDA (INR mn)	35,292	25,841	25,125	32,491	41,391
EBITDA margin (%)	23.7	19.7	17.7	20.0	21.6
Adj PAT (INR mn)	21,623	13,357	11,323	16,540	23,699
YoY (%)	14.5	(38.2)	(15.2)	46.1	43.3
Fully DEPS (INR)	73.0	45.1	38.2	55.8	80.0
RoE (%)	22.9	12.3	9.5	12.6	15.9
RoCE (%)	16.7	9.6	7.6	10.0	13.2
P/E (x)	38.8	62.8	74.1	50.7	35.4
EV/EBITDA (x)	24.9	34.3	35.2	27.0	20.8

Note: Pricing as on 30 January 2025; Source: Company, Elara Securities Estimate

Rating: Accumulate

Target Price: INR 3,071

Upside: 8%


CMP: INR 2,831

As on 30 January 2025

Key data	
Bloomberg	SRF IN
Reuters Code	SRFL.NS
Shares outstanding (mn)	296
Market cap (INR bn/USD mn)	839/9,686
Enterprise Value (INR bn/USD mn)	885/10,212
Avg daily volume 3M (INR mn/USD mn)	1,551/18
52 week high/low	2,849/2,089
Free float (%)	50

Note: as on 30 January 2025; Source: Bloomberg

Price chart



Source: Bloomberg

Source: BSE

NSE Small-cap

Shareholding (%)	Q4 FY24	Q1 FY2.5	Q2 FY25	Q3 FY25	
Promoter	50.3	50.3	50.3	50.3	
% Pledged	-	-	-	-	
FII	19.1	18.7	18.3	18.3	
DII	16.0	16.6	17.8	18.0	
Others	14.6	14.4	13.6	13.4	

 Price performance (%)
 3M
 6M
 12M

 Nifty
 (4.5)
 (6.5)
 8.0

 SRF
 25.2
 10.9
 27.4

 NSE Mid-cap
 (6.4)
 (10.1)
 10.3

(10.0)

Gagan Dixit Aviation, Chemicals, Oil & Gas +91 22 6164 8504 gagan.dixit@elaracapital.com

Associates Amogh Deshpande Kartik Bhandari



(13.8)



Financials (YE March)

Income statement (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Net revenue	148,703	131,385	142,211	162,205	191,414
EBITDA	35,292	25,841	25,125	32,491	41,391
Less: Depreciation & amortization	5,753	6,726	8,103	8,974	9,738
EBIT	29,539	19,115	17,022	23,517	31,653
Less: Interest expense	2,048	3,023	3,821	3,662	2,653
Add: Other income	749	830	1,316	1,350	1,384
PBT	28,240	16,922	14,517	21,205	30,384
Less taxes	6,617	3,565	3,194	4,665	6,684
Effective tax rate (%)	23	21	22	22	22
Reported PAT	21,623	13,357	11,323	16,540	23,699
Adjusted PAT	21,623	13,357	11,323	16,540	23,699
Balance sheet (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	2,974	2,974	2,974	2,974	2,974
Reserves	100,296	111,816	120,899	135,087	156,318
Borrowings	44,775	50,305	60,305	45,705	31,105
Deferred tax	6,993	7,002	7,002	7,002	7,002
Total liabilities	155,039	172,098	191,181	190,769	197,399
Fixed Assets	124,553	140,470	148,467	153,593	153,955
Investments	4,942	5,267	5,267	5,267	5,267
Inventories	22,743	23,265	24,392	27,370	31,767
Debtors	17,856	19,428	20,634	23,084	26,710
Cash	6,165	4,075	14,696	7,007	9,948
Loans & Advances	3,589	4,588	4,762	5,083	5,552
Other Current Assets	6,598	5,342	5,698	6,089	6,519
Net Current Assets	25,543	26,361	37,447	31,910	38,178
Total assets	155,039	172,098	191,181	190,769	197,399
Cashflow statement (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Operating cash flow	29,017	20,939	21,466	25,674	31,380
Less: Capex	(28,658)	(22,169)	(16,100)	(14,100)	(10,100)
Free cash flow to firm	360	(1,231)	5,366	11,574	21,280
Investing cash flow	(29,614)	(22,273)	(14,784)	(12,750)	(8,716)
Financing cash flow	2,196	(717)	3,940	(20,613)	(19,722)
Net change in cash	1,575	(2,087)	10,621	(7,690)	2,942
Ratio analysis	FY23	FY24	FY25E	FY26E	FY27E
Income statement ratios (%)	1123		11202	11202	11272
Revenue growth	19.6	(11.6)	8.2	14.1	18.0
EBITDA growth	13.7	(26.8)	(2.8)	29.3	27.4
PAT growth	14.5	(38.2)	(15.2)	46.1	43.3
EBITDA margin (%)	23.7	19.7	17.7	20.0	21.6
Net margin (%)	14.5	10.2	8.0	10.2	12.4
Return and liquidity ratios	20	20.2	0.0	10.2	
Interest/EBIT (x)	0.1	0.2	0.2	0.2	0.1
Net debt/equity (x)	0.4	0.4	0.4	0.3	0.1
ROA (%)	15.2	8.2	6.2	8.7	12.2
ROE (%)	22.9	12.3	9.5	12.6	15.9
ROCE (%)	16.7	9.6	7.6	10.0	13.2
Per share data and valuation ratios	20.7	,,,,	,,,,	20.0	38.4
Diluted EPS (INR)	73.0	45.1	38.2	55.8	80.0
EPS growth (%)	14.5	(38.2)	(15.2)	46.1	43.3
Book Value (INR/share)	348.6	387.5	418.2	466.1	537.7
DPS (INR)	7.2	7.2	7.6	7.9	8.3
P/E (x)	38.8	62.8	74.1	50.7	35.4
	24.9		35.2		
EV/EBITDA (x) Price/book (x)	24.9	7.3	6.8	27.0	5.3
Dividend yield (%)	0.3	0.3	0.3	0.3	0.3

Note: Pricing as on 30 January 2025; Source: Company, Elara Securities Estimate



Quarterly financials

Consolidated (INR mn)	Q3FY25	Q3FY24	YoY (%)	Q2FY25	QoQ (%)	Q3FY25E	Variance (%)	
Net operating income	34,913	30,530	14.4	14.4 34,243 2.0 30,242		30,242	15.4	
EBITDA	6,196	5,658	9.5	5,380	15.2	4,715	31.4	
Depr	(1,943)	(1,689)	15.0	(1,939)	0.2	(1,978)	(1.8)	
Interest cost	(963)	(674)	42.9	(938)	2.6	(938)	2.6	
Other income	396	188	111.4	333	18.9	300	32.1	
РВТ	3,687	3,483	5.9	2,837	30.0	2,099	75.7	
Tax	(976)	(949)	2.9	(822)	18.7	(420)	132.5	
Effective tax rate (%)	26	27		29		20		
Adj. PAT	2,711	2,534	7.0	2,014	34.6	1,679	61.4	
EPS	9.2	8.6	7.0	6.8	34.6	5.7	61.4	

Source: Company, Elara Securities Estimate

Conference call highlights

Fluorochemicals

- Domestic demand for room ACs was strong, which led to the highest-ever refrigerant gas sales.
- ▶ R-32 capacity saw 65-70% utilization in 9MFY25.
- In the HFC segment, exports grew 7-8% and the domestic segment 60% in 9MFY25.
- R32 capacity is 25,000-28,000tonnes and currently, there are no plans to expand it.
- No significant increase in prices was seen for PTFE in Q3 and SRF expects better utilization in FY26 with traction in exports markets. Some grades have been sent for sampling and are currently in the approval process.
- ▶ Export markets contribute 40-42% to HFCs in terms of tonnages.
- In HFC, domestic market sales are largely on spot basis.
- Some refrigerant gas has seen price increase in domestic and exports. SRF was hopeful that prices will remain strong. SRF expects the benefit of price hikes in some markets to flow in Q4.

Specialty Chemicals

- ▶ The segment saw YoY sales growth in 9M.
- ▶ SRF expects Q4 performance to improve further from Q3 level. It also informed that Q4 is historically a good quarter for Specialty Chemicals.
- Growth will be driven by restocking as well as underlying recovery.
- Pricing, operating leverage and volume pick-up contributed to growth in Q3, with volume pick-up being the key.
- In advanced intermediates, SRF will see traction when customers see demand and increase their production. SRF is hopeful that FY26 will be a good year for the segment.
- The effect of low-cost imports from China may be mitigated to a certain extent but not entirely, as per the management.
- > SRF is seeing some recovery in the Agrochem segment and expects Q4 to be better than Q3.
- FY26 should see higher utilization for Specialty Chemicals and capitalized capex will take 12-18 months to fully ramp up.

Packaging Films

- ▶ BOPET margins improved slightly. India BOPET demand was stable, while BOPP saw demand growth in Q3.
- Margin for the Aluminium foil segment was hit by lower-cost imports from China.
- ▶ SRF said that multiple BOPET/BOPP lines are scheduled to come online globally. However, there may be delays given the current environment.



Other highlights

- ▶ FY25 margin may be 200bps YoY against FY24 margin.
- Capex is likely to be INR 15-20bn in FY26.
- Overall reduction in interest rates may lead to some benefit in FY26, as per the management.
- ▶ Forex impact in Q3 was INR 340mn.

Exhibit 1: Valuation summary

(INR)	
WACC (%)	9.8
Terminal growth rate (%)	5
Present value of FCF (FY23-47E)	1,573
Present value of terminal value	1,482
Enterprise value (INR mn)	3,054
Net debt/(cash)	16
Equity value or target price	3,071

Source: Elara Securities Estimate


Exhibit 2: Change in estimates

(INR mn)	NR mn) Earlier			Revised			% Change		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	138,380	155,267	175,524	142,211	162,205	191,414	2.8	4.5	9.1
EBITDA	23,236	30,680	36,721	25,125	32,491	41,391	8.1	5.9	12.7
EBITDA margin (%)	16.8	19.8	20.9	17.7	20.0	21.6	88	27	70
PAT	9,900	15,274	20,115	11,323	16,540	23,699	14.4	8.3	17.8
EPS (INR)	33.4	51.6	67.9	38.2	55.8	80.0	14.4	8.3	17.8
TP (INR)			2,232			3,071			37.6
Rating			Reduce			Accumulate			

Source: Elara Securities Estimate



Coverage History



	Date	Rating	Target Price	Closing Price
1	30-Aug-2022	Buy	INR 3,085	INR 2,545
2	25-Jul-2023	Accumulate	INR 2,385	INR 2,164
3	30-Oct-2023	Accumulate	INR 2,282	INR 2,164
4	15-Nov-2023	Accumulate	INR 2,672	INR 2,361
5	31-Jan-2024	Accumulate	INR 2,538	INR 2,325
6	9-May-2024	Accumulate	INR 2,473	INR 2,291
7	24-Jul-2024	Reduce	INR 2,349	INR 2,368
8	23-Oct-2024	Reduce	INR 2,232	INR 2,248
9	30-Jan-2025	Accumulate	INR 3,071	INR 2,831

Guide to Research Rating

BUY	Absolute Return >+20%
ACCUMULATE	Absolute Return +5% to +20%
REDUCE	Absolute Return -5% to +5%
SELL	Absolute Return < -5%



Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE], in the Capital Market Segment of BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclosures for U.S. Investors

The research analyst did not receive compensation from SRF Limited.

Elara Capital Inc.'s affiliate did not manage an offering for SRF Limited

 ${\tt Elara\ Capital\ Inc.'s\ affiliate\ did\ not\ receive\ compensation\ from\ SRF\ Limited\ in\ the\ last\ 12\ months.}$

Elara Capital Inc.'s affiliate does not expect to receive compensation from SRF Limited in the next 3 months.

Disclaimer for U.S. Investors

This material is based upon information that we consider to be reliable, but Elara Capital Inc. does not warrant its completeness, accuracy or adequacy and it should not be relied upon as such.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount investmeet, where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies to you. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

Certain statements in this report, including any financial projections, may constitute "forward-looking statements." These "forward-looking statements" are not guarantees of future performance and are based on numerous current assumptions that are subject to significant uncertainties and contingencies. Actual future performance could differ materially from these "forward-looking statements" and financial information.



India

Elara Securities (India) Private Limited

One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel: +91 22 6164 8500 Europe Elara Capital Plc.

6th Floor, The Grove, 248A Marylebone Road, London, NW1 6JZ, United Kingdom Tel: +44 20 7486 9733 USA

Elara Securities Inc. 230 Park Avenue, Suite 2415, New York, NY 10169, USA Tel: +1 212 430 5870 Fax: +1 212 208 2501 Asia / Pacific Elara Capital (Asia) Pte.Ltd.

One Marina Boulevard, Level 20, Singapore 018989 Tel: +65 6978 4047



Managing Director

Harendra Kumar | harendra.kumar@elaracapital.com | +91 22 6164 8571



Head of Research

Dr Bino Pathiparampil | bino.pathiparampil@elaracapital.com | +91 22 6164 8572

Sales Team



India

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543 Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558



India, APAC & Australia Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508 Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541 Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567



India & UK

Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544



India & US

Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570



Corporate Access, Conference & Events

Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520 Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595

Access our reports on Bloomberg: Type RESP ESEC <GO>

Also available on Thomson & Reuters

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel: +91 22 6164 8500 CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933

Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ 000 238236

Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018

Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509

Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapital.com - Tel. +91 22 6164 8509